A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia

Am J Hematol. 2021 May 1;96(5):E175-E179. doi: 10.1002/ajh.26136. Epub 2021 Mar 11.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies / administration & dosage
  • Antibodies / adverse effects
  • Antibodies / therapeutic use*
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / therapeutic use*
  • Chemical and Drug Induced Liver Injury / etiology*
  • Dose-Response Relationship, Drug
  • Early Termination of Clinical Trials
  • Female
  • Humans
  • Immunoconjugates / administration & dosage
  • Immunoconjugates / adverse effects
  • Immunoconjugates / therapeutic use*
  • Lectins, C-Type / antagonists & inhibitors*
  • Lectins, C-Type / immunology
  • Leukemia, Myeloid, Acute / drug therapy*
  • Leukemia, Myeloid, Acute / genetics
  • Male
  • Middle Aged
  • Mutation
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / immunology
  • Neoplasms, Second Primary / drug therapy
  • Neoplasms, Second Primary / genetics
  • Receptors, Mitogen / antagonists & inhibitors*
  • Receptors, Mitogen / immunology
  • Young Adult

Substances

  • Antibodies
  • Antineoplastic Agents
  • CLEC12A protein, human
  • DCLL9718S
  • Immunoconjugates
  • Lectins, C-Type
  • Neoplasm Proteins
  • Receptors, Mitogen

Associated data

  • ClinicalTrials.gov/NCT03298516